Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Next Generation Spatial Genomics Tools for the Human Brain - Summary Spatial Genomics in Human Brain Tissues Has the Ability to Visualize Gene Expression Programs in Complex Cell Interactions That Are Involved in Many Neurological Disorders. However, Current Spatial Technology Is Often Limited by the High Autofluorescence in Human Brain Samples and the Poor Rna Quality. at Spatial Genomics, We Have Commercialized the Gene Positioning System (GENEPS) Platform That Is Based on the Sequential Fluorescence in Situ Hybridization (seqfish) Technology (eng Et Al, 2019) That Allows 10,000 Genes to Be Imaged Directly in Tissue Samples. the Major Goal of This Project Is to Develop Next Generation Reagents to Scale Up the Multiplexity of Assays Available on the Geneps Instrument. We Will Develop New Assays That Can Be Performed Robustly Across Human Brain Tissues by the Geneps Platform.
Committed
$2.5 Million
Paid out
$1.2M
47%
Committed, not yet paid
$1.3M
53%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…